cd22 car-transduced t cells
B-All
National Cancer Institute (NCI)Cell therapyPhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 89/ 100
Competitive context
140 Active assets in the B-All cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE University of Washington | Phase 3 | BBB |
VINCRISTINE SULFATE City of Hope Medical Center | Phase 3 | BB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) City of Hope Medical Center | Phase 3 | BB |
PEGASPARGASE National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM University of Washington | Phase 3 | BB |
View all 50 →
Same molecule, other indications
cd22 car-transduced t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →